I42.7

Cardiomyopathy due to drug and external agent

Cardiomyopathy due to drug and external agent is a myocardial disease characterized by structural and functional abnormalities of the heart muscle caused by the toxic effects of various substances. These agents include prescribed medications (particularly chemotherapeutic agents like anthracyclines or targeted therapies like trastuzumab), illicit drugs (such as cocaine and methamphetamines), and environmental toxins (such as heavy metals like cobalt, lead, or arsenic). Exposure to these agents can lead to various forms of cardiac dysfunction, most commonly manifesting as dilated cardiomyopathy with impaired systolic function. The pathophysiology often involves oxidative stress, direct cellular damage, mitochondrial dysfunction, and disrupted calcium signaling within cardiomyocytes. In clinical practice, coding requirements for I42.7 necessitate an additional code from the T36-T65 range to identify the specific drug or external agent responsible for the condition.

Clinical Symptoms

Dyspnea on exertion
Fatigue and generalized weakness
Orthopnea (shortness of breath when lying flat)
Paroxysmal nocturnal dyspnea
Peripheral edema (swelling of the ankles and feet)
Palpitations or sensation of irregular heartbeat
Chest pain or discomfort
Syncope or near-syncope
Reduced exercise tolerance
Abdominal distension or ascites
Weight gain due to fluid retention
Hepatomegaly related to venous congestion

Common Causes

Anthracycline chemotherapy (e.g., doxorubicin, daunorubicin)
Targeted cancer therapies (e.g., trastuzumab, tyrosine kinase inhibitors)
Chronic cocaine use
Methamphetamine abuse
Heavy metal toxicity (e.g., cobalt, lead, mercury, arsenic)
Radiation therapy to the chest/mediastinum
Long-term exposure to industrial chemical toxins
Adverse effects of certain antiviral or immunosuppressive medications
Chronic exposure to hydrocarbons

Documentation & Coding Tips

Specify the causative drug or external agent using clinical linkage language.

Example: Patient presents with dilated cardiomyopathy due to chronic doxorubicin therapy for breast cancer. The link is established based on the temporal relationship between chemotherapy cycles and the decline in left ventricular ejection fraction from 60 percent to 35 percent. Diagnosis: Cardiomyopathy due to drug and external agent (I42.7). Adverse effect of antineoplastic and immunosuppressive drugs (T45.1X5A). Chronic systolic heart failure (I50.22).

Billing Focus: Requires an additional code from T36-T50 to identify the drug or external agent and its intent (adverse effect versus poisoning).

Document the specific type of cardiomyopathy manifestation observed.

Example: Clinical documentation notes toxic cardiomyopathy manifesting as restrictive physiology secondary to long-term cocaine abuse. Patient remains in NYHA Class III heart failure despite cessation of the agent. Ejection fraction is preserved at 52 percent but with significant diastolic dysfunction. Diagnosis: Cardiomyopathy due to drug and external agent (I42.7). Cocaine related disorders, cocaine use, unspecified with cocaine-induced heart disease (F14.981).

Billing Focus: Documentation must specify if the heart failure is systolic, diastolic, or combined to support I50 codes.

Distinguish between adverse effect of a correctly prescribed medication and poisoning.

Example: Patient developed acute cardiomyopathy as an adverse effect of therapeutic trastuzumab treatment. This is not a poisoning or overdose. Diagnosis: Cardiomyopathy due to drug and external agent (I42.7). Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter (T45.1X5A).

Billing Focus: Sequencing is critical: I42.7 should be sequenced first, followed by the T-code for the adverse effect of the drug.

Include Heart Failure details including Ejection Fraction and NYHA classification.

Example: Toxic cardiomyopathy secondary to heavy alcohol and methamphetamine use. Ejection fraction is severely reduced at 20 percent. Patient is in acute on chronic systolic heart failure. Diagnosis: Cardiomyopathy due to drug and external agent (I42.7). Acute on chronic systolic heart failure (I50.23). Methamphetamine use, unspecified with drug-induced heart disease (F19.981).

Billing Focus: Providing the LVEF percentage allows for higher specificity coding in the I50 category.

Report chronicity and status of the condition.

Example: Patient with history of drug-induced cardiomyopathy from prior chemotherapy, now stable. Left ventricular function has recovered to 50 percent but patient requires ongoing monitoring and carvedilol therapy. Diagnosis: Cardiomyopathy due to drug and external agent (I42.7). Long term (current) use of antineoplastic agents (Z79.899).

Billing Focus: Use Z-codes to document long-term drug use that caused the cardiomyopathy.

Relevant CPT Codes

99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a Low level of medical decision making
Used for routine follow-up of stable drug-induced cardiomyopathy where medication management is straightforward.
99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a Moderate level of medical decision making
Appropriate for patients with cardiomyopathy experiencing new symptoms or requiring adjustment of multiple high-risk medications.
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a High level of medical decision making
Used for unstable patients with drug-induced cardiomyopathy who are in acute distress or require complex care coordination.
93306 - Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
The primary diagnostic tool used to identify wall motion abnormalities and calculate ejection fraction in toxic cardiomyopathy.
93000 - Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
Used to monitor for arrhythmias or QTc prolongation which are common in patients with drug-induced cardiac damage.
75557 - Cardiac magnetic resonance imaging for morphology and function without contrast material
Highly accurate for tissue characterization and identifying myocardial edema or fibrosis associated with toxic agents.
93505 - Endomyocardial biopsy
Sometimes necessary to confirm the diagnosis of toxic cardiomyopathy when imaging is inconclusive, especially in rare drug reactions.
93350 - Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test
Evaluates the cardiac reserve in patients with known drug-induced damage to determine activity tolerance.
96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
The administration service for the drugs that commonly cause the condition (e.g., anthracyclines).
93798 - Physician or other qualified health care professional services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per session)
Prescribed for patients with drug-induced cardiomyopathy once stabilized to improve functional capacity.